Rankings
Pricing
Log In
Free Trial
US-listed companies
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc.
LYRA
Market cap
$14.77M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Net loss
-22
-44
-55
Stock-based compensation
2
3
5
Depreciation
0
1
1
Loss on impairment of long-lived assets
-
-
1
Net amortization of premium on short-term investments
-
-
0
Prepaid expenses and other current assets
1
1
1
Operating lease right-of-use assets
-1
-1
1
Other assets
0
1
1
Accounts payable
0
2
-2
Accrued expenses and other current liabilities
-0
1
5
Operating lease liabilities
-1
-1
1
Deferred revenue
-
12
4
Net cash used in operating activities
-21
-26
-43
Purchases of property and equipment
2
3
0
Purchase of investments
-
-
65
Net cash used in investing activities
-2
-3
-65
Proceeds from sale of common stock and pre-funded warrants
-
-
100
Payment of deferred offering expenses
-
0
4
Proceeds from Stock Options Exercised
0
1
0
Net cash provided by financing activities
88
0
96
Net decrease in cash, cash equivalents and restricted cash
65
-29
-12
Capital Expenditures Incurred but Not yet Paid
0
0
-
Other Assets Included in Accounts Payable and Accrued Expenses
-
-
2
Modification of lease agreement
-
-
2
Deferred Offering Costs Incurred But Not Yet Paid
-
0
-